Clinical Trial

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid tumor types that express B7-H3 and PTK7.
Protocol Amendment History 1 change
notable Trial sites expanded: 5 -> 15 locations 2026-06-19
Trial Details
NCT Number NCT07503808
Lead Sponsor IDEAYA Biosciences
Conditions Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Castration-resistant Prostate Cancer, Non Small Cell Lung Cancer, Endometrium Cancer, Triple Negative Breast Cancer
Enrollment 150 participants
Start Date 2026-02-24
Primary Completion 2027-07-30 (estimated)
Study Completion 2027-07-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-18